16 Oct 10 Questions to Ask Before Buying a Pelvic Floor Chair
Medical Device Notice: Pelvic floor stimulation chairs and light therapy devices should be used only for their cleared or approved indications, within the clinician's scope of practice, and with appropriate patient screening. Contraindications vary by device and may include implanted electronic or metal devices, pregnancy, active cancer, photosensitivity or photosensitizing medications, and open wounds. Pelvic floor symptoms such as incontinence, pelvic pain or sexual dysfunction should be evaluated to identify their underlying cause before device-based treatment. This content is intended for healthcare professionals and is for general information only.
Editorial Notice: Provider rankings, recommendations and pricing in this article represent the contributor's opinion and publicly listed information at the time of writing. They are not endorsed by MedicalResearch.com or Eminent Domains Inc. Prices and product availability may change; confirm all details directly with suppliers.
A pelvic floor chair's purchase price is only the beginning of the investment. Its value depends on whether it fits your patient population, supports a clinically appropriate service, and leaves enough appointment capacity to justify the equipment and staffing costs.
For chiropractors, podiatrists, urologists, and clinic owners, early research can become confusing because pelvic health chairs and professional light therapy devices often appear in overlapping wellness discussions. They are not interchangeable. These ten questions help separate technologies, compare total costs, and identify equipment worth shortlisting.
[caption id="attachment_76603" align="aligncenter" width="500"] Pexels
Dr. Wallis[/caption]
Christopher Wallis, MD, PhD
Assistant Professor of Urology
Department of Surgery
University of Toronto and Urologic Oncologist
Mount Sinai Hospital
MedicalResearch.com: Could you give a little context - what was the question you were looking at?
Dr. Correa[/caption]
Andres F. Correa, MD
Assistant Professor
Department of Surgical Oncology, and
[caption id="attachment_57815" align="alignleft" width="150"]
Dr. Bernstein[/caption]
Adrien Bernstein, MD
Second Year Urologic Oncology Fellow
Fox Chase Cancer Center
MedicalResearch.com: What is the background for this study?
Response: Unfortunately, it has been well-established that historically Black Americans experience increased cancer specific mortality compared to white patients. In prostate cancer specifically studies have shown that when access to care is equitable this gap resolves. This suggests that biological factors are not driving these differences but rather the result of the complex interplay of social determinants and systemic inequities in our healthcare system.
Early in the pandemic, multiple studies demonstrated that minority communities disproportionately shouldered poor COVID-19 outcomes. On March 13th 2020, the American College of Surgeons recommended against elective procedures; however, the definition of an elective oncologic case was left to the discretion of the provider. As prostate cancer treatment can be safely deferred up to a year follow diagnosis, management of prostate cancer during the initial lockdown period of the COVID-19 Pandemic provided a useful analysis of the differential restrictions placed on non-emergent health care during the Pandemic.